BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

NBI-98854: Preliminary Phase IIa data

Preliminary data from an open-label, dose-escalation, Canadian Phase IIa trial in 6 evaluable schizophrenic patients with moderate to severe tardive dyskinesia showed that once-daily NBI-98854 reduced mean AIMS scores from 14.3 points at baseline to 8.4 points at...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >